Project Grant R43EY036781

Award Date 9/30/24
Completion Date 9/29/25
Dollars Obligated $306K
Federal Grant Program
93.867
Assistance Type
Project Grant
Place of Performance
Portland, OR 97229, USA
Similar Awards
This federal Project Grant award from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867) provides $881,796 to Siloam Vision, Inc. to develop two advanced, laser-based, AI-enabled retinal imaging systems. The key innovations are: A wider field-of-view camera design that can be paired with either a scanning laser ophthalmoscope (SLO) or optical coherence tomography (OCT) system, offering 2D or 3D imaging, respectively. This aims to address an unmet need in retinopathy...
This Project Grant award from the National Eye Institute (NEI), under the Vision Research federal grant program (CFDA 93.867), supports the development of innovative deep learning-based biomarkers for the diagnosis and management of optic neuropathies using optical coherence tomography (OCT) imaging. The $179,964 award to the University of California, Irvine aims to: 1) employ deep generative models to map structure-function relationships and predict visual field outcomes for optic neuropathies;...
This Project Grant award from the National Eye Institute (NEI), under the Vision Research program (CFDA 93.867), provides $256,296 to The General Hospital Corporation (Massachusetts General Hospital) to develop advanced optical coherence tomography angiography (OCTA) technology for more comprehensive imaging of the peripheral retinal microvasculature. The key goals are to: 1) create high-speed adaptive ranging OCTA instrumentation leveraging integrated photonic technologies to expand the imaging...
This Project Grant award of $580,331 from the National Eye Institute (CFDA 93.867 - Vision Research) aims to develop a deep learning-based diagnostic tool for retinopathy of prematurity (ROP), a leading cause of childhood blindness. The key products and services to be delivered under this award include: Optimizing and testing an animal-to-human (A2H) model to augment the training dataset for the deep learning-based ROP diagnostic model, using existing and newly acquired longitudinal animal ROP...
This $433,841 federal Project Grant award from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867) supports the development of computational methods and deep learning models to analyze imaging data and identify biomarkers for age-related macular degeneration (AMD). The goal is to improve understanding of AMD disease progression and response to treatment. Specifically, the project will develop deep neural network models to analyze optical coherence tomography,...
Aisight Health Inc. received a $479,580 Project Grant award from the National Institutes of Health's National Eye Institute to develop artificial intelligence tools to identify rapid glaucoma progression. The goal is to use machine learning models trained on over a decade of optical coherence tomography images, visual field tests, and clinical records for more than 9,000 glaucoma patients to more accurately and quickly determine which patients are likely to experience rapid vision loss from...
This Project Grant award from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867) supports the development of a robotically-aligned optical coherence tomography (RAOCT) system capable of automatically measuring a retinal biomarker, the outer nuclear layer (ONL) thickness, which cannot be reliably identified using standard OCT devices. The $215,454 award to Duke University aims to leverage the micrometer-scale control of the RAOCT system's sample beam to enable...
The National Eye Institute (NEI), under the federal Vision Research program (CFDA 93.867), awarded a $179,440 Project Grant to Kennesaw State University (KSU) to develop a smartphone-based retinal imaging system for detecting diabetic retinopathy in Egypt. The key products and services to be delivered under this 2-year award (3/1/2025 - 2/28/2027) include: Creating a portable and cost-effective smartphone-based retinal imaging system that enhances image quality through contrast and sharpness...
The National Eye Institute (NEI) awarded a $193,168 Project Grant (CFDA 93.867 Vision Research) to Duke University to develop a novel, auto-aligning hand-held optical coherence tomography (OCT) and OCT angiography (OCTA) probe for routine and repeatable high-quality retinal imaging in infants and children. The research aims to address the challenges associated with obtaining consistent OCT and OCTA data capture in uncooperative pediatric patients. The expected outcomes include a set of...
This Project Grant award from the National Eye Institute (NEI) under the Vision Research federal grant program (CFDA 93.867) will fund the development of a new wide-field visible-light optical coherence tomography (WF-VIS-OCT) device to evaluate the oxygen-induced retinopathy (OIR) model in rats. The $623,090 award, effective September 1, 2024, will support the Oregon Health & Science University in three main efforts: 1) developing the WF-VIS-OCT system with 5-mm transverse resolution over a...

This Project Grant award from the National Eye Institute (NEI), under the Vision Research federal grant program (CFDA 93.867), is providing $306,462 to Ifocus Imaging LLC to develop a software platform called OCT-ART-DR. The platform will automate the diagnosis and staging of diabetic retinopathy using optical coherence tomography angiography (OCTA) imaging and artificial intelligence.

The key products to be delivered under this award include: 1) Improved AI-based segmentation of OCTA image features relevant to diabetic retinopathy, such as non-perfusion area, macular retinal fluid, and retinal neovascularization; and 2) An end-to-end interpretable AI framework for automatically diagnosing diabetic retinopathy, referable diabetic retinopathy, and vision-threatening diabetic retinopathy. These capabilities will be integrated into the OCT-ART-DR platform for seamless use in clinical, research, and reading center settings. The goal is to enable more reliable and efficient diabetic retinopathy management through the adoption of this OCTA-based AI diagnostic technology.

Generated 7/1/25, 5:12 AM